Is Polybrominated diphenyl ethers (PBDEs) safe for babies and kids?

Infants face disproportionate exposure to Polybrominated diphenyl ethers (PBDEs) through dust ingestion (hand-to-mouth behavior), breast milk transfer, and dermal contact with treated textiles in cribs and car seats.

Neonates and infants up to 12 months have incomplete blood-brain barrier development, immature Phase I/II metabolic enzymes (particularly CYP3A4, UGT1A1), and higher gastrointestinal permeability. Equivalent doses produce higher internal concentrations and longer residence times.

Pregnant women and their fetuses are particularly vulnerable to PBDE toxicity. PBDEs cross the placenta readily — fetal PBDE concentrations in cord blood correlate with maternal serum levels, confirming in utero transfer. Breast milk PBDE concentrations in US women were among the highest globally prior to phase-outs, meaning breastfed infants continued to receive high postnatal PBDE doses. The developmental neurotoxicity mechanism (thyroid disruption during critical windows of brain development) makes fetal and neonatal exposure the primary concern. Animal studies demonstrate that PBDE exposure during pregnancy causes offspring hyperthyroidism, altered brain development, reduced cognitive performance, and delayed motor development. Human birth cohort studies are consistent with these findings. Women with high PBDE serum levels (reflecting pre-phase-out exposure or continued exposure from legacy foam furniture) approaching their reproductive years carry these body burdens into pregnancy. Mitigation involves reducing exposure to legacy foam products; body burden reduction through elimination of exposure sources occurs gradually given PBDE's long biological half-life (months to years for lower congeners).